Korean pharmaceutical companies are preparing to have a significant impact at this year's CPhI 2023 event, taking place in Barcelona, Spain, from Oct. 24 to 26.CPhI, the world's largest pharma-bio event, annually travels to major European countries. It serves as a crucial platform for global busines
Geo-Young, South Korea's largest pharmaceutical distributor, has categorically denied recent speculations about a possible acquisition by Zuellig Pharma, as reported by multiple news sources.Geo-Young refuted rumors suggesting that Zuellig Pharma may be seeking to purchase the company from Blackston
Gilead recently launched the first Trop-2-targeted antibody-drug conjugate (ADC), Trodelvy (sacituzumab govitecan), in Korea, providing a new treatment option for patients with metastatic triple-negative breast cancer who have limited options.Gilead began the domestic supply of Trodelvy on Wednesday
AstraZeneca's Soliris (eculizumab) has demonstrated its long-term efficacy and safety profile in a real-world study in Korean patients with paroxysmal nocturnal hemoglobinuria (PNH).The October issue of the Journal of Korean Medical Science, an international medical journal of the Korean Medical Ass
The nation's antitrust watchdog has slapped JW Pharmaceutical with a correction order and a hefty fine of 29.8 billion won ($21.9 million) for providing widespread illegal rebates to over 1,500 hospitals and clinics nationwide.This fine represents the largest ever imposed in a pharmaceutical rebate
ATGC, a Korean manufacturer of botulinum toxin (BTX), said it entered into a strategic collaboration and licensing agreement with Huadong Medicine Aesthetics Investment Limited, the parent company of Sinclair Pharma Limited, an aesthetic company based out of London, for ATGC-110, the ATGC's botulinu
The HLB Group is accelerating its entry into the European market for Rivoceranib by narrowing down its European partner candidates.HLB is to attend the European Society for Medical Oncology Annual Meeting (ESMO 2023) in Madrid, Spain, for five days from Oct. 20 to 24, operating its own booth with it
Two digital healthcare startups -- Dr. Diary and Lemon Healthcare -- have been selected as final partners for the fourth HealthX Challenge Seoul, a competition co-organized by Novartis Korea, the Seoul Metropolitan Government, and Seoul BioHub.The three co-organizers held the fourth HealthX Challeng
HLB said Jiangsu Hengrui Pharmaceuticals have signed an agreement to grant global rights, excluding Korea and China, for camrelizumab, an immunotherapy candidate in development for the treatment of hepatocellular carcinoma (HCC), to Elevar, HLB's U.S. subsidiary.HLB and Elevar now have global rights
For Vyndamax (tafamidis), a treatment for the rare disease transthyretin amyloid cardiomyopathy (ATTR-CM), to win insurance benefits, its maker, Pfizer Korea, must be more willing to share the risk, experts said last week.They shared this and other views at the insurance session of the 67th autumnal
Bayer Korea aims to transform the treatment landscape for patients with chronic heart failure with a left ventricular ejection fraction of less than 45 percent with the recent reimbursement of Verquvo (ingredient: vericiguat), the company said Monday.At the press conference celebrating the drug's re
Prestige Biopharma Group said its Kosdaq-listed Prestige Biopharma and Prestige Biologics, a biopharmaceutical contract development and manufacturing organization (CDMO), will participate in CPHI Worldwide 2023 in Barcelona, Spain, from Oct. 24-26, one of the world’s largest trade fairs for the phar
GI Innovation said it licensed out GI-301, its allergy treatment candidate, to Maruho, a Japanese pharmaceutical company specializing in dermatology.Under the accord, GI Innovation is eligible for $221 million, including non-refundable upfront payments, development and commercial milestone payments,
With the growth of the cell-gene therapy (CGT) market, the contract development and manufacturing organization (CDMO) business targeting such treatments is also growing.However, industry executives express concern about a “mismatch” between domestic CDMOs and CGT developers.Last Wednesday, Ahn Jong-
GC said it has signed a joint research and development agreement with Immetas Therapeutics, a U.S.-based pharmaceutical firm, related to mRNA therapeutics for autoimmune diseases.Through this joint research, both companies will develop autoimmune disease therapeutics using Immetas' unique platform f
Bayer Korea said it has appointed Lee Jin-a, the current CEO of Bayer Thailand, as its new CEO of Bayer Group in Korea in charge of its pharmaceutical, consumer health, and crop science divisions, effective from Nov. 1.Lee will become the first Korean CEO in Bayer Group’s Korean offshoot history.Acc
Bayer's kidney drug Kerendia (finerenone) has been recognized as adequate for receiving insurance benefits by the Pharmaceutical Reimbursement Evaluation Committee.Kolon Pharma's three-drug inhaler Trimbow (beclometasone/formoterol/glycopyrronium) and Takeda's hemophilia drug Obizur (susoctocog alph
Hanall Biopharma and Daewoong Pharmaceutical have entered clinical trials for their new pipeline, targeting the 10 trillion won ($7.46 billion) global Parkinson's disease treatment market.Hanall, Daewoong, and NurrOn Pharmaceuticals said Thursday that they have completed the first dosing of patients
MSD Korea's application for a bulk reimbursement expansion for 13 indications of Keytruda (pembrolizumab) has been rejected at the first threshold.On Wednesday, the Health Insurance Review and Assessment Service (HIRA) released the results of its deliberations on the reimbursement standards for drug
As SK chemicals moves forward with the sale of its pharmaceutical division, labor unions have declared their opposition to the sale.The union has made clear its opposition to the sale, saying that workers will have to bear the brunt of the restructuring and damages caused by the planned sale.SK chem